EU simplifies GMP template for investigational drugs
This article was originally published in SRA
The European Commission has simplified the means by which companies can certify that investigational drugs from non-EU countries comply with good manufacturing practice standards1.
You may also be interested in...
As part of efforts to “renovate” its good clinical practice (GCP) framework, the International Council for Harmonisation has framed new overarching GCP principles that can be applied to diverse trial types and data sources.
The 2021 work plan of PIC/S, the international group of pharmaceutical inspectorates, includes renewed efforts to carry out projects that could not be completed due to the coronavirus pandemic.
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a recently formed regulatory oversight group has identified several topics requiring further scientific discussion.